ABTB3: A Potential Drug Target and Biomarker (G121551)

Target Name: ABTB3

NCBI ID: G121551

ABTB3

ABTB3: A Potential Drug Target and Biomarker

ABTB3, or Ankyrin repeat and BTB/POZ domain-containing protein BTBD11, is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The ABTB3 protein is a member of the BTB/POZ domain family, which is characterized by the presence of a long terminal repeat and a BTB/POZ domain. This family of proteins has been implicated in a variety of cellular processes, including cell signaling, DNA replication, and protein-protein interactions.

The BTBD11 protein is a 21-kDa protein that is expressed in a variety of tissues, including brain, muscle, and placenta. It is highly conserved, with a calculated pI of 6.5 and predicted a localization in the cytoplasm. The protein is associated with Various cellular processes, including cell adhesion, migration, and stress response.

In addition to its putative role in cellular processes, the ABTB3 protein is also a potential drug target. Its BTB/POZ domain has been shown to interact with various drug targets, including the protein kinase Akt (AKT) and the transcription factorPDGF2. These interactions suggest that the ABTB3 protein may play a role in modulating cellular signaling pathways that are affected by drugs.

The ABTB3 protein has also been shown to be involved in a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These diseases are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroglial cells. The ABTB3 protein is thought to contribute to the development and progression of these diseases by participating in the regulation of cellular processes that are important for brain function.

In addition to its potential role in neurodegenerative diseases, the ABTB3 protein is also associated with an increased risk of cancer. This is because the BTB/POZ domain is known to be involved in the regulation of cell cycle progression, and the consequences of disrupted cell cycle regulation have been implicated in the development of cancer. The ABTB3 protein may also contribute to the development of cancer by regulating cellular signaling pathways that are important for cell growth and survival.

In conclusion, the ABTB3 protein is a promising drug target and biomarker for a variety of diseases. Its BTB/POZ domain and its expression in various tissues make it a promising target for small molecules and other therapeutic agents. Further research is needed to fully understand the role of the ABTB3 protein in cellular processes and its potential as a drug target.

Protein Name: Ankyrin Repeat And BTB Domain Containing 3

The "ABTB3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABTB3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets